Lorena Garcia Conde

850 total citations · 2 hit papers
22 papers, 571 citations indexed

About

Lorena Garcia Conde is a scholar working on Surgery, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lorena Garcia Conde has authored 22 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 8 papers in Economics and Econometrics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lorena Garcia Conde's work include Lipoproteins and Cardiovascular Health (12 papers), Asthma and respiratory diseases (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Lorena Garcia Conde is often cited by papers focused on Lipoproteins and Cardiovascular Health (12 papers), Asthma and respiratory diseases (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Lorena Garcia Conde collaborates with scholars based in Switzerland, United Kingdom and United States. Lorena Garcia Conde's co-authors include Wolfgang Köenig, Kausik K. Ray, Frederick J. Raal, Ulf Landmesser, Lawrence A. Leiter, Gregory G. Schwartz, R. Scott Wright, Mark Jaros, David Kallend and Andrew Friedman and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and PEDIATRICS.

In The Last Decade

Lorena Garcia Conde

21 papers receiving 562 citations

Hit Papers

Pooled Patient-Level Analysis of Inclisiran Trials in Pat... 2021 2026 2022 2024 2021 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
    2021 159 citations R. Scott Wright, Kausik K. Ray et al. Journal of the American College of Cardiology profile →
  2. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
    2022 131 citations Kausik K. Ray, Frederick J. Raal et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lorena Garcia Conde Switzerland 10 360 132 125 113 98 22 571
Bei Wang China 8 515 1.4× 153 1.2× 37 0.3× 61 0.5× 102 1.0× 26 631
Jonathan Fialkow United States 12 539 1.5× 224 1.7× 105 0.8× 42 0.4× 247 2.5× 29 1.0k
Ioanna Gouni-Berthold Germany 4 358 1.0× 155 1.2× 23 0.2× 22 0.2× 108 1.1× 6 599
John T. Monyak United States 11 449 1.2× 123 0.9× 28 0.2× 53 0.5× 246 2.5× 23 652
H Vaverková Czechia 13 226 0.6× 46 0.3× 47 0.4× 33 0.3× 200 2.0× 71 526
Martín Lobo Argentina 13 247 0.7× 41 0.3× 40 0.3× 43 0.4× 218 2.2× 68 599
P.J. Barter Australia 9 539 1.5× 43 0.3× 31 0.2× 51 0.5× 300 3.1× 13 742
Jane K. Stock France 9 263 0.7× 95 0.7× 31 0.2× 16 0.1× 90 0.9× 40 436
Razvan T. Dadu United States 8 179 0.5× 48 0.4× 22 0.2× 57 0.5× 32 0.3× 16 403
Márcia Martins Silveira Bernik Brazil 14 215 0.6× 29 0.2× 45 0.4× 31 0.3× 78 0.8× 22 551

Countries citing papers authored by Lorena Garcia Conde

Since Specialization
Citations

This map shows the geographic impact of Lorena Garcia Conde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorena Garcia Conde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorena Garcia Conde more than expected).

Fields of papers citing papers by Lorena Garcia Conde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorena Garcia Conde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorena Garcia Conde. The network helps show where Lorena Garcia Conde may publish in the future.

Co-authorship network of co-authors of Lorena Garcia Conde

This figure shows the co-authorship network connecting the top 25 collaborators of Lorena Garcia Conde. A scholar is included among the top collaborators of Lorena Garcia Conde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorena Garcia Conde. Lorena Garcia Conde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Landmesser, Ulf, Wolfgang Köenig, Lawrence A. Leiter, et al.. (2025). Efficacy and safety of inclisiran based on background lipid-lowering treatment. European Journal of Preventive Cardiology. 2 indexed citations
2.
3.
Wright, R. Scott, Kausik K. Ray, Ulf Landmesser, et al.. (2024). Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease. Mayo Clinic Proceedings. 99(8). 1222–1235. 7 indexed citations
4.
Leiter, Lawrence A., Frederick J. Raal, Gregory G. Schwartz, et al.. (2024). Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials. Diabetes Obesity and Metabolism. 26(8). 3223–3237. 13 indexed citations
5.
Köenig, Wolfgang, Kausik K. Ray, Ulf Landmesser, et al.. (2023). Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. SHILAP Revista de lepidopterología. 14. 100503–100503. 11 indexed citations
6.
Landmesser, Ulf, Wolfgang Köenig, Lawrence A. Leiter, et al.. (2023). Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 386. 117354–117354. 7 indexed citations
7.
Ray, Kausik K., Frederick J. Raal, David Kallend, et al.. (2022). Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. 44(2). 129–138. 131 indexed citations breakdown →
8.
Hanania, Nicola A., Robert Niven, Pascal Chanez, et al.. (2022). Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal. 15(10). 100695–100695. 12 indexed citations
9.
Köenig, Wolfgang, Lorena Garcia Conde, Ulf Landmesser, et al.. (2022). Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovascular Drugs and Therapy. 38(3). 493–503. 23 indexed citations
10.
Landmesser, Ulf, Kausik K. Ray, Frederick J. Raal, et al.. (2021). EFFICACY AND SAFETY OF INCLISIRAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A POOLED ANALYSIS FROM THREE PHASE 3 CLINICAL TRIALS (ORION-9, -10 AND -11). Journal of the American College of Cardiology. 77(18). 1458–1458. 2 indexed citations
11.
Wright, R. Scott, Kausik K. Ray, Frederick J. Raal, et al.. (2021). Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Journal of the American College of Cardiology. 77(9). 1182–1193. 159 indexed citations breakdown →
12.
Landmesser, Ulf, Lorena Garcia Conde, R. Scott Wright, et al.. (2021). Effect of inclisiran on haematological and immunological biomarkers: A Pooled analysis of ORION-9, -10 and -11 trial data. Atherosclerosis. 331. e37–e37. 1 indexed citations
13.
Köenig, Wolfgang, Kausik K. Ray, Ulf Landmesser, et al.. (2021). Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials. European Heart Journal. 42(Supplement_1). 2 indexed citations
14.
Köenig, Wolfgang, Kausik K. Ray, Ulf Landmesser, et al.. (2021). Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials. European Heart Journal. 42(Supplement_1). 3 indexed citations
15.
16.
17.
Busse, William W., Marc Humbert, Tmirah Haselkorn, et al.. (2019). Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Annals of Allergy Asthma & Immunology. 124(2). 190–196. 34 indexed citations
18.
Κatsaounou, Paraskevi, Mikaëla Odemyr, Michael E. Hyland, et al.. (2018). Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Research. 4(4). 76–2018. 27 indexed citations
19.
Busse, William W., Marc Humbert, Patricia Stephenson, et al.. (2018). The effect of omalizumab on lung function in adolescents with moderate to severe allergic asthma. PEDIATRICS. 142(1_MeetingAbstract). 809–809. 2 indexed citations
20.
Κatsaounou, Paraskevi, Lorena Garcia Conde, Claus Kroegel, et al.. (2017). Living with severe asthma year 2016. PA4682–PA4682.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bei Wang Breakdown of academic impact, for papers by Jonathan Fialkow Breakdown of academic impact, for papers by Ioanna Gouni-Berthold Breakdown of academic impact, for papers by John T. Monyak Breakdown of academic impact, for papers by H Vaverková Breakdown of academic impact, for papers by Martín Lobo Breakdown of academic impact, for papers by P.J. Barter Breakdown of academic impact, for papers by Jane K. Stock Breakdown of academic impact, for papers by Razvan T. Dadu Breakdown of academic impact, for papers by Márcia Martins Silveira Bernik
Rankless by CCL
2026